Genetic Breakthrough in Combating Drug-Resistant Leukemia

Researchers from Duke-NUS Medical School, along with collaborators, have uncovered a crucial **genetic variation** among East Asians that significantly contributes to drug resistance in **chronic myeloid leukemia (CML)**. This variation affects a protein known as **BIM**, which is integral to the process of cellular apoptosis, or programmed cell death, a mechanism frequently harnessed by cancer treatments to eradicate tumor cells. The study, published in the journal _Leukemia_, highlights the **prevalence of the BIM variation** among 12-15% of East Asians, which results in altered versions of the BIM protein, thereby aiding cancer cells in evading cell death. This resistance has notably been observed in patients undergoing treatment with **tyrosine kinase inhibitors**, like imatinib, a common therapeutic agent for CML. Intrigued by these findings, the research team focused their efforts on understanding the cellular dependencies of these drug-resistant cancer cells. They identified that cancer cells harboring the BIM variation exhibited a strong reliance on a protein called **MCL-1** for survival. The innovative approach of combining an MCL-1 inhibitor with imatinib demonstrated significant effectiveness in pre-clinical models, suggesting a promising new therapeutic strategy for overcoming drug resistance in CML. **This breakthrough underscores the potential application of genetic profiling in cancer therapies, emphasizing the importance of early genetic testing for improving patient outcomes.** Furthermore, these insights may have broader implications for other cancers, such as certain lung cancers, where similar mechanisms might be at play. The research team expresses hope for extending the benefits of **precision medicine** to a wider range of patients, highlighting Duke-NUS's role in advancing cancer research and treatment globally.